Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Delcath Systems, Inc. - Common Stock (NQ:DCTH)

11.69 +0.75 (+6.86%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,043,923
Open	11.41
Bid (Size)	11.65 (100)
Ask (Size)	11.74 (600)
Prev. Close	10.94
Today's Range	11.25 - 12.17
52wk Range	8.120 - 16.68
Shares Outstanding	7,906,728
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

May 26, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026

From Delcath Systems, Inc.

Via Business Wire

Performance

YTD	+17.5%	+17.5%
1 Month	+5.7%	+5.7%
3 Month	+24.8%	+24.8%
6 Month	+18.0%	+18.0%
1 Year	-26.7%	-26.7%

More News

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath (DCTH) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

Delcath Systems (NASDAQ:DCTH) Surpasses Q1 Estimates, Guidance Points to Continued Growth ↗

May 07, 2026

Via Chartmill

Delcath Systems Inc (NASDAQ:DCTH) Posts Q4 Beat, Provides Cautious 2026 Outlook ↗

February 26, 2026

Via Chartmill

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

May 07, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

May 07, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Host First Quarter 2026 Earnings Call

April 23, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

April 06, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

April 01, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

March 03, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath (DCTH) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Via The Motley Fool

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

February 26, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

February 12, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 27, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 21, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

January 09, 2026

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

December 31, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

December 03, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

November 20, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

November 18, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 14, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

November 13, 2025

From Delcath Systems, Inc.

Via Business Wire

Delcath Systems to Participate in Upcoming Investor Conferences

November 06, 2025

From Delcath Systems, Inc.

Via Business Wire

Frequently Asked Questions

Is Delcath Systems, Inc. - Common Stock publicly traded?

Yes, Delcath Systems, Inc. - Common Stock is publicly traded.

What exchange does Delcath Systems, Inc. - Common Stock trade on?

Delcath Systems, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Delcath Systems, Inc. - Common Stock?

The ticker symbol for Delcath Systems, Inc. - Common Stock is DCTH on the Nasdaq Stock Market

What is the current price of Delcath Systems, Inc. - Common Stock?

The current price of Delcath Systems, Inc. - Common Stock is 11.69

When was Delcath Systems, Inc. - Common Stock last traded?

The last trade of Delcath Systems, Inc. - Common Stock was at 06/09/26 04:00 PM ET

What is the market capitalization of Delcath Systems, Inc. - Common Stock?

The market capitalization of Delcath Systems, Inc. - Common Stock is 92.43M

How many shares of Delcath Systems, Inc. - Common Stock are outstanding?

Delcath Systems, Inc. - Common Stock has 92M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.